Observational Study in Adults With Severe Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP) Treated With Dupilumab in France
Latest Information Update: 14 Oct 2024
At a glance
- Drugs Dupilumab (Primary)
- Indications Nasal polyps; Rhinosinusitis
- Focus Adverse reactions; Therapeutic Use
- Acronyms OPALE
- Sponsors Sanofi
- 09 Oct 2024 Planned End Date changed from 18 Sep 2026 to 21 Sep 2026.
- 09 Oct 2024 Status changed from recruiting to active, no longer recruiting.
- 07 May 2024 New trial record